Dynamic regulation of phenylalanine hydroxylase

Pteridines

Volumn 25, Issue 2, 2014, Pages 33-39

  Fuchs, Julian E ^a,b   Fuchs, Dietmar ^c   Liedl, Klaus R ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Allostery; Conformational dynamics; Molecular dynamics simulation; Phenylalanine hydroxylase; Regulation

Indexed keywords

PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; TETRAHYDROBIOPTERIN;

ALLOSTERISM; COMPUTER MODEL; CONFORMATIONAL TRANSITION; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 84908554507     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines-2014-0006     Document Type: Short Survey

References (71)

1. Fitzpatrick PF. Mechanism of aromatic amino acid hydroxylation. Biochemistry 2003;42:14083-91.
2. Centerwall WR, Centerwall SA. Phenylketonuria (Folling's disease). The story of its discovery. J Hist Med 1961;16:292-6.
3. Williams RA, Marnotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev 2008;29:31-41.
4. Bik-Multanowski M, Peitrzyk JJ. LAT1 gene variants - potential factors influencing the clinical course of phenylketonuria. J Inherit Metab Dis 2006;29:684-6.
5. Scriver CR. The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat 2007;28:831-45.
6. Pey AL, Stricher F, Serrano L, Martinez A. Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am J Hum Genet 2007;81:1006-24.
7. Gersting SW, Kemter KF, Staudigl M, Messing DD, Danecka MK, Lagler FB, et al. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am J Hum Genet 2008;83:5-17.
8. Daubner SC, Hillas PJ, Fitzpatrick PF. Expression and characterization of the catalytic domain of human phenylalanine hydroxylase. Arch Biochem Biophys 1997;348:295-302.
9. Kobe B, Jennings IG, House CM, Michell BJ, Goodwill KE, Santasiero BD, et al. Structural basis of autoregulation of phenylalanine hydroxylase. Nat Struct Biol 1999;6:442-8.
10. Fusetti F, Erlandsen H, Flatmark T, Stevens RC. Structure of tetrameric human phenylalanine hydroxylase and its implications for phenylketonuria. J Biol Chem 1998;273:16962-7.
11. Miranda FF, Teigen K, Thorolfsson M, Svebak RM, Knappskog PM, Flatmark T, et al. Phosphorylation and mutations of Ser(16) in human phenylalanine hydroxylase. Kinetic and structural effects. J Biol Chem 2002;277:40937-43.
12. Jaffe EK, Stith L, Lawrence SH, Andrake M, Dunbrack RL, Jr. A new model for allosteric regulation of phenylalanine hydroxylase: implications for disease and therapeutics. Arch Biochem Biophys 2013;530:73-82.
13. Flydal MI, Martinez A. Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life 2013;65:341-9.
14. Nielsen KH. Rat liver phenylalanine hydroxylase. A method for the measurement of activity, with particular reference to the distinctive features of the enzyme and the pteridine cofactor. Eur J Biochem 1969;7:360-9.
15. Shiman R, Gray DW. Substrate activation of phenylalanine hydroxylase. A kinetic characterization. J Biol Chem 1980;255:4793-800.
16. Gjetting T, Petersen M, Guldberg P, Guttler F. Missense mutations in the N-terminal domain of human phenylalanine hydroxylase interfere with binding of regulatory phenylalanine. Am J Hum Genet 2001;68:1353-60.
17. Martinez A, Haavik J, Flatmark T. Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase. Eur J Biochem 1990;193:211-9.
18. Thorolfsson M, Ibarra-Molero B, Fojan P, Petersen SB, Sanchez-Ruiz JM, Martinez A. L-phenylalanine binding and domain organization in human phenylalanine hydroxylase: a differential scanning calorimetry study. Biochemistry 2002;41:7573-85.
19. Andersen OA, Flatmark T, Hough E. High resolution crystal structure of the catalytic domain of human phenylalanine hydroxylase in its catalytically active Fe(II) form and binary complex with tetrahydrobiopterin. J Mol Biol 2001;314:279-91.
20. Andersen OA, Stokka AJ, Flatmark T, Hough E. 2.0A resolution structure of the ternary complexes of human phenylalanine hydroxylase catalytic domain with tetrahydrobiopterin and 3-(2-thienyl)-L-alanine or L-norleucine: substrate specificity and molecular motions related to substrate binding. J Mol Biol 2000;333:747-57.
21. Santos-Sierra S, Kirchmair J, Perna AM, Reiss D, Kemter K, Roschinger W, et al. Novel pharmacological chaperones that correct phenylketonuria in mice. Hum Mol Genet 2012;21:1877-87.
22. Fitzpatrick PF. Allosteric regulation of phenylalanine hydroxylase. Arch Biochem Biophys 2012;519:194-201.
23. Tsai CJ, Nussinov R. A unified view of "how allostery works". PLoS Comput Biol 2014;20:e1003394.
24. Frauenfelder H, Sligar SG, Wolynes PG. The energy landscapes and motions of proteins. Science 1991;254(5038):1598-603.
25. Erlandsen H, Pey AL, Gamez A, Perez B, Desviat LR, Aquado C, et al. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci USA 2004;101:16903-8.
26. Shiman R, Mortimore GE, Schworer CM, Gray DW. Regulation of phenylalanine hydroxylase activity by phenylalanine in vivo, in vitro, and in perfused rat liver. J Biol Chem 1982;257:11213-6.
27. Shiman R, Gray DW, Pater A. A simple purification of phenylalanine hydroxylase by substrate-induced hydrophobic chromatography. J Biol Chem 1979;254:11300-6.
28. Koizumi S, Tanaka F, Kaneda N, Kano K, Nagatsu T. Nanosecond pulse fluorometry of conformational change in phenylalanine hydroxylase associated with activation. Biochemistry 1988;27:640-6.
29. Shiman R, Jones SH, Gray DW. Mechanism of phenylalanine regulation of phenylalanine hydroxylase. J Biol Chem 1990;265:11633-42.
30. Shiman R, Xia T, Hill MA, Gray DW. Regulation of rat liver phenylalanine hydroxylase: II. Substrate binding and role of activation in the control of enzymatic activity. J Biol Chem 1994;269:24647-56.
31. Flydal MI, Mohn TC, Pey AL, Stiltberg-Liberles J, Teigen K, Martinez A. Superstoichiometric binding of L-Phe to phenylalanine hydroxylase from Caenorhabditis elegans: evolutionary implications. Amino Acids 2010;39:1463-75.
32. Pey AL, Thorolfsson M, Teigen K, Ugarte M, Martinez A. Thermodynamic characterization of the binding of tetrahydrobiopterins to phenylalanine hydroxylase. J Am Chem Soc 2004;126:13670-8.
33. Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab 2011;104 Suppl:S2-9.
34. Kaufman S. The phenylalanine hydroxylating system. Adv Enzymol Relat Areas Mol Biol 1993;67:77-264.
35. Kowlessur D, Yang XJ, Kaufman S. Further studies of the role of Ser-16 in the regulation of the activity of phenylalanine hydroxylase. Proc Natl Acad Sci USA 1995;92:4743-7.
36. Abita JP, Milstien S, Chang N, Kaufman S. In vitro activation of rat liver phenylalanine hydroxylase by phosphorylation. J Biol Chem 1976;251:5310-4.
37. Doskeland AP, Martinez A, Knappskog PM, Flatmark T. Phosphorylation of recombinant human phenylalanine hydroxylase: effect on catalytic activity, substrate activation and protection against non-specific cleavage of the fusion protein by restriction protease. Biochem J 1996;313:409-14.
38. Li J, Fitzpatrick PF. Regulation of phenylalanine hydroxylase: conformational changes upon phosphorylation detected by H/D exchange and mass spectrometry. Arch Biochem Biophys 2013;535:115-9.
39. Fisher DB, Kaufman S. The stimulation of rat liver phenylalanine hydroxylase by phospholipids. J Biol Chem 1972;247:2250-2.
40. Parniak MA, Kaufman S. Rat liver phenylalanine hydroxylase. Activation by sulfhydryl modification. J Biol Chem 1981;256:6876-82.
41. Gibbs BS, Benkovic SJ. Affinity labeling of the active site and the reactive sulfhydryl associated with activation of rat liver phenylalanine hydroxylase. Biochemistry 1991;30:6795-802.
42. Ploder M, Neurauter G, Spittler A, Schroecksnadel K, Roth E, Fuchs D. Serum phenylalanine in patients post trauma and with sepsis correlate to neopterin concentrations. Amino Acids 2008;35:303-7.
43. Zangerle R, Kurz K, Neurauter G, Kitchen M, Sarcletti M, Fuchs D. Increased blood phenylalanine to tyrosine ratio in HIV-1 infection and correction following effective antiretroviral therapy. Brain Behav Immun 2010;24:403-8.
44. Thorolfsson M, Teigen K, Martinez A. Activation of phenylalanine hydroxylase: effect of substitutions at Arg68 and Cys237. Biochemistry 2003;42:3419-28.
45. Selwood T, Jaffe EK. Dynamic dissociating homo-oligomers and the control of protein function. Arch Biochem Biophys 2012;519:131-43.
46. Jaffe EK. Impact of quaternary structure dynamics on allosteric drug discovery. Curr Top Med Chem 2013;13:55-63.
47. Li J, Dangott LJ, Fitzpatrick PF. Regulation of phenylalanine hydroxylase: conformational changes upon phenylalanine binding detected by hydrogen/deuterium exchange and mass spectrometry. Biochemistry 2010;49:3327-35.
48. Stokka AJ, Carvalho RN, Barroso JF, Flatmark T. Probing the role of crystallographically defined/predicted hinge-bending regions in the substrate-induced global conformational transition and catalytic activation of human phenylalanine hydroxylase by single-site mutagenesis. J Biol Chem 2004;279:26571-80.
49. Jennings IG, Teh T, Kobe B. Essential role of the N-terminal autoregulatory sequence in the regulation of phenylalanine hydroxylase. FEBS Lett 2001;488:196-200.
50. Jaffe EK, Stith L. ALAD porphyria is a conformational disease. Am J Hum Genet 2007;80:329-37.
51. Karplus M, McCammon JA. Molecular dynamics simulations of biomolecules. Nat Struct Biol 2002;9:646-52.
52. Dror RO, Dirks RM, Grossman JP, Xu H, Shaw DE. Biomolecular simulation: a computational microscope for molecular biology. Annu Rev Biophys 2012;41:429-52.
53. Hodak H. The Nobel Prize in chemistry 2013 for the development of multiscale models of complex chemical systems: a tribute to Martin Karplus, Michael Levitt and Arieh Warshel. J Mol Biol 2014;426:1-3.
54. Goetz AW, Williamson MJ, Xu D, Poole D, LeGrand S, Walker RC. Routine microsecond molecular dynamics simulations with AMBER on GPUs: 1. Generalized Born. J Chem Theory Comput 2012;8:1542-55.
55. Shaw DE, Maragakis P, Lindorff-Larsen K, Piana S, Dror RO, Eastwood MP, et al. Atomic-level characterization of the structural dynamics of proteins. Science 2010;330:341-6.
56. Buch I, Giorgino T, De Fabritiis G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc Natl Acad Sci USA 2011;108:10184-9.
57. Dror RO, Green HF, Valant C, Borhani DW, Valcourt JR, Pan AC, et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 2013;503:295-9.
58. Fuchs JE, von Grafenstein S, Huber RG, Wallnoefer HG, Liedl KR. Specificity of a protein-protein interface: local dynamics direct substrate recognition of effector caspases. Proteins 2014;82: 546-55.
59. Piana S, Lindorff-Larsen K, Shaw DE. Atomic-level description of ubiquitin folding. Proc Natl Acad Sci USA 2013;110:5915-20.
60. Piana S, Lindorff-Larsen K, Shaw DE. Atomistic description of the folding of a dimeric protein. J Phys Chem B 2013;117:12935-42.
61. Teigen K, Martinez A. Probing cofactor specificity in phenylalanine hydroxylase by molecular dynamics simulations. J Biomol Struct Dyn 2003;20:733-40.
62. Pey AL, Martinez A, Charubala R, Maitland DJ, Teigen K, Calvo A, et al. Specific interaction of the diastereomers 7(R)- and 7(S)-tetrahydrobiopterin with phenylalanine hydroxylase: implications for understanding primapterinuria and vitiligo. FASEB J 2006;20:2130-2.
63. Chadha N, Tiwari AK, Kumas V, Milton MD, Mishra AK. In silico thermodynamics stability change analysis involved in BH4 responsive mutations in phenylalanine hydroxylase: QM/MM and MD simulations analysis. J Biomol Struct Dyn 2014;epub ahead of print. DOI: 10.1080/07391102.2014.897258.
64. Carluccio C, Fraternali F, Salvatore F, Fornili A, Zagari A. Structural features of the regulatory ACT domain of phenylalanine hydroxylase. PLoS One 2013;8:e79482.
65. Miranda FF, Thorolfsson M, Teigen K, Sanchez-Ruiz JM, Martinez A. Structural and stability effects of phosphorylation: localized structural changes in phenylalanine hydroxylase. Protein Sci 2004;13:1219-26.
66. Fuchs JE, Huber RG, von Grafenstein S, Wallnoefer HG, Spitzer GM, Fuchs D, et al. Dynamics regulation of phenylalanine hydroxylase by simulated redox manipulation. PLoS ONE 2012;7:e53005.
67. Ronau JA, Paul LN, Fuchs JE, Corn IR, Wagner KT, Liedl KR, et al. An additional substrate binding site in a bacterial phenylalanine hydroxylase. Eur Biophys J 2013;42:691-708.
68. Roe DR, Cheatham TE III. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 2013;9:3084-95.
69. Teeter MM, Case DA. Harmonic and quasiharmonic descriptions of crambin. J Phys Chem 1990;94:8091-7.
70. Von Grafenstein S, Wallnoefer HG, Kirchmair J, Fuchs JE, Huber RG, Schmidtke M, et al. Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity. J Biomol Struct Dyn 2013;epub ahead of print. DOI: 10.1080/07391102.2013.855142.
71. Neurauter G, Schroecksnadel K, Scholl-Buergi S, Sperner-Unterweger B, Schubert C, Ledochowski M, et al. Chronic immune stimulation correlates with reduced phenylalanine turn-over. Curr Drug Metabol 2008;9:622-7.